1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Human Plasma-derived Hyperimmune Product Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Human Plasma-derived Hyperimmune Product by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Human Plasma-derived Hyperimmune Product by Country/Region, 2018, 2022 & 2029
2.2 Human Plasma-derived Hyperimmune Product Segment by Type
2.2.1 Hepatitis B Immunoglobulins
2.2.2 Rabies Immunoglobulins
2.2.3 Tetanus Immunoglobulins
2.2.4 Rho(D) Immunoglobulins
2.2.5 Other
2.3 Human Plasma-derived Hyperimmune Product Sales by Type
2.3.1 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2018-2023)
2.3.2 Global Human Plasma-derived Hyperimmune Product Revenue and Market Share by Type (2018-2023)
2.3.3 Global Human Plasma-derived Hyperimmune Product Sale Price by Type (2018-2023)
2.4 Human Plasma-derived Hyperimmune Product Segment by Application
2.4.1 Government Institution
2.4.2 Private Sector
2.4.3 Others
2.5 Human Plasma-derived Hyperimmune Product Sales by Application
2.5.1 Global Human Plasma-derived Hyperimmune Product Sale Market Share by Application (2018-2023)
2.5.2 Global Human Plasma-derived Hyperimmune Product Revenue and Market Share by Application (2018-2023)
2.5.3 Global Human Plasma-derived Hyperimmune Product Sale Price by Application (2018-2023)
3 Global Human Plasma-derived Hyperimmune Product by Company
3.1 Global Human Plasma-derived Hyperimmune Product Breakdown Data by Company
3.1.1 Global Human Plasma-derived Hyperimmune Product Annual Sales by Company (2018-2023)
3.1.2 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Company (2018-2023)
3.2 Global Human Plasma-derived Hyperimmune Product Annual Revenue by Company (2018-2023)
3.2.1 Global Human Plasma-derived Hyperimmune Product Revenue by Company (2018-2023)
3.2.2 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Company (2018-2023)
3.3 Global Human Plasma-derived Hyperimmune Product Sale Price by Company
3.4 Key Manufacturers Human Plasma-derived Hyperimmune Product Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Plasma-derived Hyperimmune Product Product Location Distribution
3.4.2 Players Human Plasma-derived Hyperimmune Product Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Human Plasma-derived Hyperimmune Product by Geographic Region
4.1 World Historic Human Plasma-derived Hyperimmune Product Market Size by Geographic Region (2018-2023)
4.1.1 Global Human Plasma-derived Hyperimmune Product Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Human Plasma-derived Hyperimmune Product Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Human Plasma-derived Hyperimmune Product Market Size by Country/Region (2018-2023)
4.2.1 Global Human Plasma-derived Hyperimmune Product Annual Sales by Country/Region (2018-2023)
4.2.2 Global Human Plasma-derived Hyperimmune Product Annual Revenue by Country/Region (2018-2023)
4.3 Americas Human Plasma-derived Hyperimmune Product Sales Growth
4.4 APAC Human Plasma-derived Hyperimmune Product Sales Growth
4.5 Europe Human Plasma-derived Hyperimmune Product Sales Growth
4.6 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Growth
5 Americas
5.1 Americas Human Plasma-derived Hyperimmune Product Sales by Country
5.1.1 Americas Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023)
5.1.2 Americas Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023)
5.2 Americas Human Plasma-derived Hyperimmune Product Sales by Type
5.3 Americas Human Plasma-derived Hyperimmune Product Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Plasma-derived Hyperimmune Product Sales by Region
6.1.1 APAC Human Plasma-derived Hyperimmune Product Sales by Region (2018-2023)
6.1.2 APAC Human Plasma-derived Hyperimmune Product Revenue by Region (2018-2023)
6.2 APAC Human Plasma-derived Hyperimmune Product Sales by Type
6.3 APAC Human Plasma-derived Hyperimmune Product Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Human Plasma-derived Hyperimmune Product by Country
7.1.1 Europe Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023)
7.1.2 Europe Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023)
7.2 Europe Human Plasma-derived Hyperimmune Product Sales by Type
7.3 Europe Human Plasma-derived Hyperimmune Product Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Plasma-derived Hyperimmune Product by Country
8.1.1 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023)
8.1.2 Middle East & Africa Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023)
8.2 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Type
8.3 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Plasma-derived Hyperimmune Product
10.3 Manufacturing Process Analysis of Human Plasma-derived Hyperimmune Product
10.4 Industry Chain Structure of Human Plasma-derived Hyperimmune Product
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Plasma-derived Hyperimmune Product Distributors
11.3 Human Plasma-derived Hyperimmune Product Customer
12 World Forecast Review for Human Plasma-derived Hyperimmune Product by Geographic Region
12.1 Global Human Plasma-derived Hyperimmune Product Market Size Forecast by Region
12.1.1 Global Human Plasma-derived Hyperimmune Product Forecast by Region (2024-2029)
12.1.2 Global Human Plasma-derived Hyperimmune Product Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Plasma-derived Hyperimmune Product Forecast by Type
12.7 Global Human Plasma-derived Hyperimmune Product Forecast by Application
13 Key Players Analysis
13.1 CSL Behring
13.1.1 CSL Behring Company Information
13.1.2 CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.1.3 CSL Behring Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 CSL Behring Main Business Overview
13.1.5 CSL Behring Latest Developments
13.2 Grifols
13.2.1 Grifols Company Information
13.2.2 Grifols Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.2.3 Grifols Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Grifols Main Business Overview
13.2.5 Grifols Latest Developments
13.3 Biotest
13.3.1 Biotest Company Information
13.3.2 Biotest Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.3.3 Biotest Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Biotest Main Business Overview
13.3.5 Biotest Latest Developments
13.4 Kedrion
13.4.1 Kedrion Company Information
13.4.2 Kedrion Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.4.3 Kedrion Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Kedrion Main Business Overview
13.4.5 Kedrion Latest Developments
13.5 CBPO
13.5.1 CBPO Company Information
13.5.2 CBPO Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.5.3 CBPO Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 CBPO Main Business Overview
13.5.5 CBPO Latest Developments
13.6 Emergent (Cangene)
13.6.1 Emergent (Cangene) Company Information
13.6.2 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.6.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Emergent (Cangene) Main Business Overview
13.6.5 Emergent (Cangene) Latest Developments
13.7 Kamada
13.7.1 Kamada Company Information
13.7.2 Kamada Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.7.3 Kamada Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Kamada Main Business Overview
13.7.5 Kamada Latest Developments
13.8 CNBG
13.8.1 CNBG Company Information
13.8.2 CNBG Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.8.3 CNBG Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 CNBG Main Business Overview
13.8.5 CNBG Latest Developments
13.9 Hualan Bio
13.9.1 Hualan Bio Company Information
13.9.2 Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.9.3 Hualan Bio Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Hualan Bio Main Business Overview
13.9.5 Hualan Bio Latest Developments
13.10 Shanghai RAAS
13.10.1 Shanghai RAAS Company Information
13.10.2 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.10.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Shanghai RAAS Main Business Overview
13.10.5 Shanghai RAAS Latest Developments
13.11 Sichuan Yuanda Shuyang
13.11.1 Sichuan Yuanda Shuyang Company Information
13.11.2 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.11.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Sichuan Yuanda Shuyang Main Business Overview
13.11.5 Sichuan Yuanda Shuyang Latest Developments
13.12 ADMA Biologics
13.12.1 ADMA Biologics Company Information
13.12.2 ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 ADMA Biologics Main Business Overview
13.12.5 ADMA Biologics Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Human Plasma-derived Hyperimmune Product Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Human Plasma-derived Hyperimmune Product Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Hepatitis B Immunoglobulins
Table 4. Major Players of Rabies Immunoglobulins
Table 5. Major Players of Tetanus Immunoglobulins
Table 6. Major Players of Rho(D) Immunoglobulins
Table 7. Major Players of Other
Table 8. Global Human Plasma-derived Hyperimmune Product Sales by Type (2018-2023) & (K Units)
Table 9. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2018-2023)
Table 10. Global Human Plasma-derived Hyperimmune Product Revenue by Type (2018-2023) & ($ million)
Table 11. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2018-2023)
Table 12. Global Human Plasma-derived Hyperimmune Product Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global Human Plasma-derived Hyperimmune Product Sales by Application (2018-2023) & (K Units)
Table 14. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2018-2023)
Table 15. Global Human Plasma-derived Hyperimmune Product Revenue by Application (2018-2023)
Table 16. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application (2018-2023)
Table 17. Global Human Plasma-derived Hyperimmune Product Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global Human Plasma-derived Hyperimmune Product Sales by Company (2018-2023) & (K Units)
Table 19. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Company (2018-2023)
Table 20. Global Human Plasma-derived Hyperimmune Product Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Company (2018-2023)
Table 22. Global Human Plasma-derived Hyperimmune Product Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers Human Plasma-derived Hyperimmune Product Producing Area Distribution and Sales Area
Table 24. Players Human Plasma-derived Hyperimmune Product Products Offered
Table 25. Human Plasma-derived Hyperimmune Product Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Human Plasma-derived Hyperimmune Product Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Human Plasma-derived Hyperimmune Product Sales Market Share Geographic Region (2018-2023)
Table 30. Global Human Plasma-derived Hyperimmune Product Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Human Plasma-derived Hyperimmune Product Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Country/Region (2018-2023)
Table 34. Global Human Plasma-derived Hyperimmune Product Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023) & (K Units)
Table 37. Americas Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2018-2023)
Table 38. Americas Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Human Plasma-derived Hyperimmune Product Revenue Market Share by Country (2018-2023)
Table 40. Americas Human Plasma-derived Hyperimmune Product Sales by Type (2018-2023) & (K Units)
Table 41. Americas Human Plasma-derived Hyperimmune Product Sales by Application (2018-2023) & (K Units)
Table 42. APAC Human Plasma-derived Hyperimmune Product Sales by Region (2018-2023) & (K Units)
Table 43. APAC Human Plasma-derived Hyperimmune Product Sales Market Share by Region (2018-2023)
Table 44. APAC Human Plasma-derived Hyperimmune Product Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Human Plasma-derived Hyperimmune Product Revenue Market Share by Region (2018-2023)
Table 46. APAC Human Plasma-derived Hyperimmune Product Sales by Type (2018-2023) & (K Units)
Table 47. APAC Human Plasma-derived Hyperimmune Product Sales by Application (2018-2023) & (K Units)
Table 48. Europe Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023) & (K Units)
Table 49. Europe Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2018-2023)
Table 50. Europe Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Human Plasma-derived Hyperimmune Product Revenue Market Share by Country (2018-2023)
Table 52. Europe Human Plasma-derived Hyperimmune Product Sales by Type (2018-2023) & (K Units)
Table 53. Europe Human Plasma-derived Hyperimmune Product Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Human Plasma-derived Hyperimmune Product Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Human Plasma-derived Hyperimmune Product
Table 61. Key Market Challenges & Risks of Human Plasma-derived Hyperimmune Product
Table 62. Key Industry Trends of Human Plasma-derived Hyperimmune Product
Table 63. Human Plasma-derived Hyperimmune Product Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Human Plasma-derived Hyperimmune Product Distributors List
Table 66. Human Plasma-derived Hyperimmune Product Customer List
Table 67. Global Human Plasma-derived Hyperimmune Product Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Human Plasma-derived Hyperimmune Product Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Human Plasma-derived Hyperimmune Product Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Human Plasma-derived Hyperimmune Product Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Human Plasma-derived Hyperimmune Product Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Human Plasma-derived Hyperimmune Product Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Human Plasma-derived Hyperimmune Product Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Human Plasma-derived Hyperimmune Product Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Human Plasma-derived Hyperimmune Product Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Human Plasma-derived Hyperimmune Product Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Human Plasma-derived Hyperimmune Product Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Human Plasma-derived Hyperimmune Product Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Human Plasma-derived Hyperimmune Product Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. CSL Behring Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 82. CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 83. CSL Behring Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. CSL Behring Main Business
Table 85. CSL Behring Latest Developments
Table 86. Grifols Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 87. Grifols Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 88. Grifols Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Grifols Main Business
Table 90. Grifols Latest Developments
Table 91. Biotest Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 92. Biotest Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 93. Biotest Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Biotest Main Business
Table 95. Biotest Latest Developments
Table 96. Kedrion Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 97. Kedrion Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 98. Kedrion Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. Kedrion Main Business
Table 100. Kedrion Latest Developments
Table 101. CBPO Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 102. CBPO Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 103. CBPO Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. CBPO Main Business
Table 105. CBPO Latest Developments
Table 106. Emergent (Cangene) Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 107. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 108. Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Emergent (Cangene) Main Business
Table 110. Emergent (Cangene) Latest Developments
Table 111. Kamada Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 112. Kamada Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 113. Kamada Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 114. Kamada Main Business
Table 115. Kamada Latest Developments
Table 116. CNBG Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 117. CNBG Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 118. CNBG Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 119. CNBG Main Business
Table 120. CNBG Latest Developments
Table 121. Hualan Bio Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 122. Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 123. Hualan Bio Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 124. Hualan Bio Main Business
Table 125. Hualan Bio Latest Developments
Table 126. Shanghai RAAS Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 127. Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 128. Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 129. Shanghai RAAS Main Business
Table 130. Shanghai RAAS Latest Developments
Table 131. Sichuan Yuanda Shuyang Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 132. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 133. Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 134. Sichuan Yuanda Shuyang Main Business
Table 135. Sichuan Yuanda Shuyang Latest Developments
Table 136. ADMA Biologics Basic Information, Human Plasma-derived Hyperimmune Product Manufacturing Base, Sales Area and Its Competitors
Table 137. ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
Table 138. ADMA Biologics Human Plasma-derived Hyperimmune Product Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 139. ADMA Biologics Main Business
Table 140. ADMA Biologics Latest Developments
List of Figures
Figure 1. Picture of Human Plasma-derived Hyperimmune Product
Figure 2. Human Plasma-derived Hyperimmune Product Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Plasma-derived Hyperimmune Product Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Human Plasma-derived Hyperimmune Product Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Human Plasma-derived Hyperimmune Product Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Hepatitis B Immunoglobulins
Figure 10. Product Picture of Rabies Immunoglobulins
Figure 11. Product Picture of Tetanus Immunoglobulins
Figure 12. Product Picture of Rho(D) Immunoglobulins
Figure 13. Product Picture of Other
Figure 14. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type in 2022
Figure 15. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Type (2018-2023)
Figure 16. Human Plasma-derived Hyperimmune Product Consumed in Government Institution
Figure 17. Global Human Plasma-derived Hyperimmune Product Market: Government Institution (2018-2023) & (K Units)
Figure 18. Human Plasma-derived Hyperimmune Product Consumed in Private Sector
Figure 19. Global Human Plasma-derived Hyperimmune Product Market: Private Sector (2018-2023) & (K Units)
Figure 20. Human Plasma-derived Hyperimmune Product Consumed in Others
Figure 21. Global Human Plasma-derived Hyperimmune Product Market: Others (2018-2023) & (K Units)
Figure 22. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2022)
Figure 23. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Application in 2022
Figure 24. Human Plasma-derived Hyperimmune Product Sales Market by Company in 2022 (K Units)
Figure 25. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Company in 2022
Figure 26. Human Plasma-derived Hyperimmune Product Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Company in 2022
Figure 28. Global Human Plasma-derived Hyperimmune Product Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Human Plasma-derived Hyperimmune Product Sales 2018-2023 (K Units)
Figure 31. Americas Human Plasma-derived Hyperimmune Product Revenue 2018-2023 ($ Millions)
Figure 32. APAC Human Plasma-derived Hyperimmune Product Sales 2018-2023 (K Units)
Figure 33. APAC Human Plasma-derived Hyperimmune Product Revenue 2018-2023 ($ Millions)
Figure 34. Europe Human Plasma-derived Hyperimmune Product Sales 2018-2023 (K Units)
Figure 35. Europe Human Plasma-derived Hyperimmune Product Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Human Plasma-derived Hyperimmune Product Revenue 2018-2023 ($ Millions)
Figure 38. Americas Human Plasma-derived Hyperimmune Product Sales Market Share by Country in 2022
Figure 39. Americas Human Plasma-derived Hyperimmune Product Revenue Market Share by Country in 2022
Figure 40. Americas Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2018-2023)
Figure 41. Americas Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2018-2023)
Figure 42. United States Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Human Plasma-derived Hyperimmune Product Sales Market Share by Region in 2022
Figure 47. APAC Human Plasma-derived Hyperimmune Product Revenue Market Share by Regions in 2022
Figure 48. APAC Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2018-2023)
Figure 49. APAC Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2018-2023)
Figure 50. China Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Human Plasma-derived Hyperimmune Product Sales Market Share by Country in 2022
Figure 58. Europe Human Plasma-derived Hyperimmune Product Revenue Market Share by Country in 2022
Figure 59. Europe Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2018-2023)
Figure 60. Europe Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2018-2023)
Figure 61. Germany Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Human Plasma-derived Hyperimmune Product Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Market Share by Application (2018-2023)
Figure 70. Egypt Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Human Plasma-derived Hyperimmune Product Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Human Plasma-derived Hyperimmune Product in 2022
Figure 76. Manufacturing Process Analysis of Human Plasma-derived Hyperimmune Product
Figure 77. Industry Chain Structure of Human Plasma-derived Hyperimmune Product
Figure 78. Channels of Distribution
Figure 79. Global Human Plasma-derived Hyperimmune Product Sales Market Forecast by Region (2024-2029)
Figure 80. Global Human Plasma-derived Hyperimmune Product Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Human Plasma-derived Hyperimmune Product Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Human Plasma-derived Hyperimmune Product Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Human Plasma-derived Hyperimmune Product Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Human Plasma-derived Hyperimmune Product Revenue Market Share Forecast by Application (2024-2029)

※参考情報 ヒト血漿由来高度免疫製品（Human Plasma-derived Hyperimmune Product）は、免疫グロブリン（抗体）を豊富に含有し、特定の病原体に対する防御効果を強化した血漿由来の製品です。これらの製品は、主に特定の感染症に対する治療や予防のために使用され、医療現場で重要な役割を果たしています。 ヒト血漿由来高度免疫製品は、一般的にヒトの血漿から抽出された免疫グロブリンを濃縮し、特定の抗体を強化したものです。これらの製品は、特定の感染症や病気に対する患者の免疫力をサポートするために設計されています。例えば、特定のウイルスや細菌に対する抗体を高濃度で含む血漿を用いることで、感染症の予防や治療の効果を高めることができます。 この製品の特徴として、まず第一に、その高い抗体濃度が挙げられます。通常の免疫製品と比較して、特定の病原体に対する抗体が濃縮されるため、より強力な免疫反応を期待できます。また、ヒト由来であるため、動物由来の製品と比べて免疫抑制のリスクが低く、高い安全性が保証されています。さらに、これらの製品は特定の病原体に対する迅速な応答を可能にするため、緊急の医療ニーズに対応するために迅速に使用されることができるのも大きな特徴です。 ヒト血漿由来高度免疫製品の種類には、様々なものがあります。一般的なものとしては、免疫グロブリン療法に使用される免疫グロブリン製剤などが挙げられます。また、特定のウイルスや病原体に特化した製品も存在します。例えば、乙型肝炎ウイルスに対する抗体を高濃度で含む製品、あるいはインフルエンザウイルスに対する製品などがあります。これらは、特定の感染症が流行している際に、リスクの高い患者に対して迅速に提供されることが求められます。 使用される用途として、ヒト血漿由来高度免疫製品は主に感染症の予防および治療に用いられることが多いです。これに加えて、某種の疾患に対する免疫力の低下を補うために使用されることもあります。また、特定の病原体に対して高い抗体価を持つ製品は、特定の職業や地域において合併症のリスクが高い人々に対する予防的な手段としても活用されます。 関連技術については、ヒト血漿由来高度免疫製品の製造過程において、さまざまな高度な技術が用いられています。まず、血漿の収集にはドナーからの献血が必要であり、その後、厳密な管理の下で採取された血漿は、成分分離や濃縮のプロセスを経て製品化されます。これには、ウイルス不活化技術や純化技術が含まれ、製品の安全性を確保するために欠かせません。例えば、ウイルス不活化のためには、加熱処理や化学薬品の使用が行われることがあります。 さらに、最新の技術革新により、ヒト血漿由来の高度免疫製品はますます進化しています。新たなフィルター技術や分離技術が開発され、より高純度で高効率の抗体製品が生産されるようになっています。これにより、患者に提供される製品の質が向上し、治療効果も高まることが期待されています。 ヒト血漿由来高度免疫製品は、特にパンデミックや流行性疾病の際に、その重要性が際立ちます。例えば、COVID-19のような新しい病原体が出現した場合、適切な高度免疫製品の開発と供給が、感染症の管理において重要なカギとなります。近年の研究では、こうした製品が新興感染症対策の一環としての役割を果たすことが確認されています。 また、社会全体における健康促進の観点からも、これらの製品の需要は増加しています。免疫機能の強化が注目される中で、ヒト血漿由来の高度免疫製品は、医療従事者や高リスク群の人々にとって、より良い健康管理手段とされており、その応用範囲は今後ますます広がることが期待されています。 このように、ヒト血漿由来高度免疫製品は、確かな基盤の上に成立する科学技術の成果であり、感染症対策や免疫療法において重要な役割を果たしています。今後も研究開発が進んでいく中で、より効果的かつ安全な製品の開発が期待されています。また、国々や地域によって異なる感染症のプロファイルに応じた、カスタマイズされた製品の必要性が高まることも予測されます。これら全ての要素が一体となり、ヒト血漿由来高度免疫製品の未来を切り開いていくことになります。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer